Analysts Adjust Price Targets for Carlsmed Following Q3 Results
Following the company's Q3 2026 earnings report, Needham and Truist Securities raised their price targets for Carlsmed.
Stocks · News reference
Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78M
Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nvidia To $200? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts cut targets for AMBQ, TYRA, NVDA, HUBB and CAN; raised CARL and RIOT targets, while downgrading NVDA and RIOT.
Carlsmed Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Carlsmed, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting 65% revenue growth and an upward revision to its full-year 2026 revenue outlook.
Carlsmed, Inc. Announces Third Quarter 2026 Earnings Release Date
Carlsmed, Inc. has scheduled the release of its third quarter 2026 financial results for November 10, 2026.
Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
Carlsmed, Inc. announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting. The launch follows a limited market evaluation that began in February 2026. The system leverages the company's AI-enabled software platform to deliver personalized spine fusion solutions, with endorsements from surgeons at University of Colorado and Mayo Clinic.
BTIG Maintains Buy on Carlsmed, Raises Price Target to $24
BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $23 to $24.